Oculis Holding AG is a clinical-stage biopharmaceutical company located in Zug, Switzerland, focusing on the development of treatments for ophthalmic, neuro-ophthalmic, and neurological diseases. Established in 2017, it was initially named Oculis SA and rebranded to its current name in March 2023. The company employs around 60 staff members and is listed on multiple stock exchanges, including the NASDAQ Global Market under the ticker symbol "OCS" and the Nasdaq Iceland Main Market since April 23, 2024. Oculis has a focused product portfolio featuring several drug candidates: - **OCS-01** is a topical dexamethasone formulation currently in Phase 3 trials aimed at treating diabetic macular edema. - **OCS-02** is a topical biologic candidate in Phase 2b trials for dry eye disease. - **OCS-05** is a disease-modifying neuroprotective agent in development for conditions including glaucoma and diabetic retinopathy. In April 2024, Oculis raised approximately $59 million through a registered direct offering, selling 5,000,000 ordinary shares to accelerate its clinical development efforts, especially for OCS-05. As of August 24, 2026, the company’s stock was priced at $13.18 per share, with a market capitalization of approximately $813.63 million.
AI-researched from public web sources, not from the exchange listing itself — may contain errors or omissions and is not a substitute for verifying independently.
Oculis Holding AG's offering is currently approved on OTHER. Oculis Holding AG is headquartered in Iceland. It is classified under Biotech.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Oculis Holding AG.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/oculis" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Oculis Holding AG — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/oculis?theme=light as the src instead.
https://www.discoveripo.com/ipo/oculis/opengraph-image
Oculis Holding AG IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/oculis?utm_source=embed&utm_medium=text&utm_campaign=oculis
Get emailed when Oculis Holding AG's terms, price, or expected date change — no weekly noise, just this company.
Oculis Holding AG is listing on OTHER.
Oculis Holding AG is a clinical-stage biopharmaceutical company located in Zug, Switzerland, focusing on the development of treatments for ophthalmic, neuro-ophthalmic, and neurological diseases. Established in 2017, it was initially named Oculis SA and rebranded to its current name in March 2023. The company employs around 60 staff members and is listed on multiple stock exchanges, including the NASDAQ Global Market under the ticker symbol "OCS" and the Nasdaq Iceland Main Market since April 23, 2024. Oculis has a focused product portfolio featuring several drug candidates: - **OCS-01** is a topical dexamethasone formulation currently in Phase 3 trials aimed at treating diabetic macular edema. - **OCS-02** is a topical biologic candidate in Phase 2b trials for dry eye disease. - **OCS-05** is a disease-modifying neuroprotective agent in development for conditions including glaucoma and diabetic retinopathy. In April 2024, Oculis raised approximately $59 million through a registered direct offering, selling 5,000,000 ordinary shares to accelerate its clinical development efforts, especially for OCS-05. As of August 24, 2026, the company’s stock was priced at $13.18 per share, with a market capitalization of approximately $813.63 million.
European Securities and Markets Authority's Prospectus Regulation register — a prospectus approval date, not a confirmed listing date. Retrieved Aug 26, 2026.
View the original filing on ESMA →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy